• A focus on innovation

    Bringing first in class products to the underserved dermatology market

  • Building a franchise in chronic pruritus

  • Low Systemic Exposure platform underpins our growing pipeline

  • Experienced Management Team and Board

Creabilis completes EU FP7 project and selects two novel drug candidates for further development in atopic dermatitis and psoriasis  Read more >>
Creabilis appoints Catherine Moukheibir as Chairman of its Board of Director  Read more >>
United Kingdom
6 Denne Hill Business Centre
Womenswold
Canterbury, CT4 6HD
Italy
Creabilis Therapeutics Srl
Via Ribes, 5
10010 Colleretto Giacosa (TO)

About Creabilis

  1. Company Profile
  2. Senior Management
  3. Board of Directors
  4. Scientific Advisory Board

Therapeutic Focus

  1. Dermatology
  2. Chronic Pruritus
  3. Low Systemic Exposure

Products

  1. Pipeline
  2. CT327
  3. CT340
  4. Other Pipeline Products

Investor Relations

  1. Overview

News & Events

  1. Press Releases
  2. Events
  3. Sign up to News

Contact us

  1. Location
  2. Careers
  • A focus on innovation

    Bringing first in class products to the underserved dermatology market

  • Building a franchise in chronic pruritus

  • Low Systemic Exposure platform underpins our growing pipeline

  • Experienced Management Team and Board

Creabilis completes EU FP7 project and selects two novel drug candidates for further development in atopic dermatitis and psoriasis  Read more >>
Creabilis appoints Catherine Moukheibir as Chairman of its Board of Director  Read more >>